COMPANY Data
Movers and SHAKERS

Ticker | BTAI (Nasdaq) |
Current Price | $13.42 ↑ 0.13 |
Market Cap | 375.56M |
Volume | 246.00k |
52wk Range | $9.08 - $39.00 |
ADVANCED MARKET DATA |

Advanced Market Data
BioXcel Therapeutics Inc. (BTAI)Overview
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company which is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, which is a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company's other product candidates are BXCL502 and BXCL702 which is focused on neurodegeneration and hematological malignancies.
- BioXcel begins a new stage with IGALMI in the commercialization process.
- With a current market cap of just $300 million, I think BioXcel offers an excellent investment opportunity right now.
- I believe that BioXcel could reach a capitalization of between $1 billion and $1.5 billion without much trouble in the coming months.
For further details see:
BioXcel's Igalmi: Potential Market For Acute Agitation In Esquizofrenia And Bipolar PatientsBioXcel Therapeutics Inc. Corporate Filings
BioXcel Therapeutics Inc. Corporate Events
BioXcel Therapeutics Inc. Press Releases / News Feed
Channelchek
Not available
Channelchek
No reports available